Compare Moderna, Inc. (MRNA) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Realty Income Corp — how do they compare? Moderna, Inc. trades at $218.26 (market cap $78.65B), while Realty Income Corp trades at $54 (market cap $51.26B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Realty Income Corp pays a 6.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Realty Income Corp for 127 Days on average.
| MRNA | O | |
|---|---|---|
Market Cap | $78.65B | $51.26B |
Volume | 37,373,437 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $203.46 | $67.56 |
52-Week Low | $22.36 | $53.35 |
Typical Hold Time | 59 Days | 127 Days |
Enterprise Value | $74.80B | $81.88B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Realty Income (O) trades at $53.35, down 1.66% amid a bearish technical signal, with support at $52. The stock has missed EPS estimates for three consecutive quarters but maintains a 92.56% gross margin and 21.23% net income margin. Recent news highlights its 6% dividend yield and 136 consecutive dividend increases, though rising Treasury yields pressure REIT valuations.
The outlook is mixed: analyst consensus targets $64.80 (21% upside) with a 'Hold' bias, but debt-to-asset ratios have risen to 39.93% (2025). Key risks include interest rate sensitivity and earnings misses, while the dividend track record offers income stability. Investors face trade-offs between yield sustainability and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
